Jazz Pharmaceuticals
| Company type | Public |
|---|---|
| Industry | |
| Predecessor | Jazz Pharmaceuticals, Inc. (before the 2012 tax inversion to Ireland) |
| Founded | 2003 in California, U.S. |
| Headquarters | Dublin, Ireland |
Area served | Worldwide |
Key people | Bruce C. Cozadd (chairman and CEO) |
| Products | Pharmaceutical drugs |
| Brands | |
| Revenue | US$3.83 billion (2023) |
| US$579 million (2023) | |
| US$415 million (2023) | |
| Total assets | US$11.4 billion (2023) |
| Total equity | US$3.74 billion (2023) |
Number of employees | c. 2,800 (2023) |
| Website | jazzpharma |
| Footnotes / references | |
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).